Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Report Pursuant to Section 28a of the Danish Securities Trading Act18 Jan 2011
Genmab's Financial Calendar for 201116 Dec 2010
Articles of Association of Genmab A/S15 Dec 2010
Grant of Warrants to Management and Employees in Genmab A/S9 Dec 2010
Report Pursuant to Section 28a of the Danish Securities Trading Act9 Dec 2010
Interim Report for the 9 Months Ended September 30, 20109 Nov 2010
Genmab Announces Results for the Nine Month Period of 2010 and Updated 2010 Financial Guidance9 Nov 2010
Multiple Ofatumumab and Daratumumab Abstracts to Be Presented at ASH Annual Meeting
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
8 Nov 2010
Articles of Association27 Oct 2010
Genmab Announces Start of Ofatumumab Phase III Head to Head Study in Follicular Lymphoma26 Oct 2010
Genmab Announces Reorganization Plan25 Oct 2010
Arzerra Third Quarter 2010 Net Sales Figures21 Oct 2010
  • Previous
  • 1
  • More pages
  • 98
  • 99
  • 100
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863